Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance

被引:12
|
作者
Zhang, Haozhe [1 ]
Zhou, Yi [1 ]
Xing, Zengzhen [1 ]
Sah, Rajiv Kumar [1 ]
Hu, Junqi [1 ]
Hu, Hailiang [1 ,2 ]
机构
[1] So Univ Sci & Technol, Sch Med, Dept Biochem, Shenzhen 518055, Peoples R China
[2] Southern Univ Sci & Technol, Key Univ Lab Metab & Hlth Guangdong, Shenzhen 518055, Peoples R China
基金
中国国家自然科学基金;
关键词
androgen metabolism; androgen receptor; anti-androgen therapy; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; UDP-GLUCURONOSYLTRANSFERASES; INDEPENDENT GROWTH; CYP17A1; INHIBITION; BACKDOOR PATHWAY; RECEPTOR; CASTRATION; TESTOSTERONE; ABIRATERONE; EXPRESSION;
D O I
10.3390/ijms232113521
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
All aspects of prostate cancer evolution are closely related to androgen levels and the status of the androgen receptor (AR). Almost all treatments target androgen metabolism pathways and AR, from castration-sensitive prostate cancer (CSPC) to castration-resistant prostate cancer (CRPC). Alterations in androgen metabolism and its response are one of the main reasons for prostate cancer drug resistance. In this review, we will introduce androgen metabolism, including how the androgen was synthesized, consumed, and responded to in healthy people and prostate cancer patients, and discuss how these alterations in androgen metabolism contribute to the resistance to anti-androgen therapy.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
    Li, Zhenfei
    Alyamani, Mohammad
    Li, Jianneng
    Rogacki, Kevin
    Abazeed, Mohamed
    Upadhyay, Sunil K.
    Balk, Steven P.
    Taplin, Mary-Ellen
    Auchus, Richard J.
    Sharifi, Nima
    [J]. NATURE, 2016, 533 (7604) : 547 - +
  • [2] Third generation anti-androgen therapy of advanced prostate cancer
    Ohlmann, C. -H.
    Kamradt, J.
    Stoeckle, M.
    [J]. UROLOGE, 2012, 51 (04): : 522 - 526
  • [3] Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
    Zhenfei Li
    Mohammad Alyamani
    Jianneng Li
    Kevin Rogacki
    Mohamed Abazeed
    Sunil K. Upadhyay
    Steven P. Balk
    Mary-Ellen Taplin
    Richard J. Auchus
    Nima Sharifi
    [J]. Nature, 2016, 533 : 547 - 551
  • [4] Prevalence of osteoporosis in patients with prostate cancer on anti-androgen therapy
    Senan Sanz, M. R.
    Haro Iniesta, L.
    Riel Cabrera, R.
    Olive Ferre, F. X.
    Biel Arrufat, A.
    Matinero Romero, E.
    [J]. SWISS MEDICAL WEEKLY, 2009, 139 (33-34) : 151S - 151S
  • [5] Anti-androgen monotherapy for metastatic prostate cancer
    Attard, Gerhardt
    [J]. LANCET ONCOLOGY, 2014, 15 (06): : 543 - 544
  • [6] Macrophages promote anti-androgen resistance in prostate cancer bone disease
    Li, Xue-Feng
    Selli, Cigdem
    Zhou, Han-Lin
    Cao, Jian
    Wu, Shuiqing
    Ma, Ruo-Yu
    Lu, Ye
    Zhang, Cheng-Bin
    Xun, Bijie
    Lam, Alyson D.
    Pang, Xiao-Cong
    Fernando, Anu
    Zhang, Zeda
    Unciti-Broceta, Asier
    Carragher, Neil O.
    Ramachandran, Prakash
    Henderson, Neil C.
    Sun, Ling-Ling
    Hu, Hai-Yan
    Li, Gui-Bo
    Sawyers, Charles
    Qian, Bin-Zhi
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2023, 220 (04):
  • [7] Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
    Florian Handle
    Stefan Prekovic
    Christine Helsen
    Thomas Van den Broeck
    Elien Smeets
    Lisa Moris
    Roy Eerlings
    Sarah El Kharraz
    Alfonso Urbanucci
    Ian G. Mills
    Steven Joniau
    Gerhardt Attard
    Frank Claessens
    [J]. Scientific Reports, 9
  • [8] Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
    Handle, Florian
    Prekovic, Stefan
    Helsen, Christine
    Van den Broeck, Thomas
    Smeets, Elien
    Moris, Lisa
    Eerlings, Roy
    El Kharraz, Sarah
    Urbanucci, Alfonso
    Mills, Ian G.
    Joniau, Steven
    Attard, Gerhardt
    Claessens, Frank
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [9] Macrophage promotion of anti-androgen resistance in prostate cancer bone disease
    Li, Xue-Feng
    Selli, Cigdem
    Unciti-Broceta, Asier
    Carragher, Neil O.
    Hu, Hai-Yan
    Sawyers, Charles L.
    Qian, Bin-Zhi
    [J]. CANCER IMMUNOLOGY RESEARCH, 2022, 10 (01)
  • [10] Re: Redirecting Abiraterone Metabolism to Fine-Tune Prostate Cancer Anti-Androgen Therapy
    Taneja, Samir S.
    [J]. JOURNAL OF UROLOGY, 2016, 196 (05): : 1447 - 1447